In this issue:
Neoadjuvant atezolizumab efficacious for resectable early-stage NSCLC
Neoadjuvant durvalumab for resectable NSCLC
Osimertinib safe in elderly patients with EGFR mutated NSCLC
Prevalence of EGFR mutations and PD-L1 expression in NSCLC in Brazil
NEJ009: PFS benefit to gefitinib plus chemotherapy in EGFR mutated NSCLC
Lorlatinib superior to crizotinib for ALK-positive NSCLC
Aprepitant rapidly alleviates EGFRTKI-induced pruritus
Nivolumab + docetaxel prolongs survival vs nivolumab for previously treated NSCLC
ARROW: pralsetinib demonstrates efficacy in RET fusion-positive NSCLC
Front-line anlotinib plus platinumetoposide for extensive-stage SCLC
Please login below to download this issue (PDF)